

## Instructions to Authors 2014

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

*Tables.* Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios  
 International Institute of Anticancer Research (IIAR)  
 Editorial Office of ANTICANCER RESEARCH,  
 IN VIVO, CANCER GENOMICS and PROTEOMICS.  
 1st km Kapandritiou-Kalamou Road  
 P.O. Box 22, GR-19014 Kapandriti, Attiki  
 GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

# in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

## General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iv.iiarjournals.org](http://www.iv.iiarjournals.org)

## Selection of Recent Articles

Cryopreservation of Viable Human Lung Tissue for Versatile Post-thaw Analyses and Culture. J.E. BAATZ, D.A. NEWTON, E.C. RIEMER, C.E. DENLINGER, E.E. JONES, R.R. DRAKE, D.D. SPYROPOULOS (*Charleston, SC, USA*)

Establishment and Characterization of New Orthotopic and Metastatic Neuroblastoma Models. E. DAUDIGEOS-DUBUS, L. LE DRET, V. ROUFFIAC, O. BAWA, I. LEGUERNEY, P. OPOLON, G. VASSAL, B. GEOERGER (*Orsay; Villejuif, France*)

Comparative Study of Prescribing Patterns of Tigecycline for Trial-Patients versus Non-Trial-Patients. J.J. HORSCHT, J.B. ZIMMERMANN, M.A. WEIGAND, T. BRUCKNER, E.O. MARTIN, T. HOPPE-TICHY, S. SWOBODA (*Heidelberg; Gießen, Germany*)

Effects of the Bifunctional Sulfoxide MMS350, A Radiation Mitigator, on Hematopoiesis in Long-Term Bone Marrow Cultures and on Radioresistance of Marrow Stromal Cell Lines. A. SHINDE, M.W. EPPERLY, S. CAO, D. FRANICOLA, D. SHIELDS, H. WANG, P. WIPF, M.M. SPRACHMAN, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

The Need for Surgery in Acute Abdominal Pain: A Randomized Study of Abdominal Computed Tomography. P. JUVONEN, T. LEHTIMÄKI, M. ESKELINEN, I. ILVES, R. VANNINEN, P. MIETTINEN, H. PAAJANEN (*Kuopio, Finland*)

Inhibitory Action of Levocetirizine on the Production of Eosinophil Chemoattractants RANTES and Eotaxin In Vitro and In Vivo. A. KANEI, K. ASANO, K.-I. KANAI, A. FURUTA, K. SASAKI, H. SUZAKI (*Tokyo; Yokohama, Japan*)

Poor Memory Performance in Aged Cynomolgus Monkeys with Hippocampal Atrophy, Depletion of Amyloid Beta 1-42 and Accumulation of Tau Proteins in Cerebrospinal Fluid. H.S. DARUSMAN, J. PANDELAKI, R. MULYADI, D. SAJUTHI, I.A. PUTRI, O.H. KALLIOKOSKI, J. CALL, K.S.P. ABELSON, S.J. SCHAPIRO, A. GJEDDE, J. HAU (*Copenhagen; Aarhus, Denmark; Jakarta; Bogor, Indonesia; Leipzig, Germany; Bastrop, TX; Baltimore, MD, USA; Montreal, QC, Canada*)

Effects of Interactions between Progesterone and Prostaglandin on Uterine Contractility in Perfused Swine Uterus Model. J. KÜNZEL, K. GEISLER, T. MALTARIS, A. MÜLLER, I. HOFFMANN, H. SCHNEIDER, M.W. BECKMANN, R. DITTRICH, P.G. OPPELT (*Erlangen, Germany*)

Esophageal Radioprotection in Thoracic Irradiated Mice with Transgenic Lung Tumors by Swallowed JP4-039/F15. M.W. EPPERLY, J.P. GOFF, D. FRANICOLA, H. WANG, P. WIPF, S. LI, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. E. SMOLLE, V. TAUCHER, J. HAYBAECK (*Graz, Austria*)

Increased DNA Integrity in Colorectal Cancer. G. LESZINSKI, J. LEHNER, U. GEZER, S. HOLDENRIEDER (*Munich; Bonn, Germany; Istanbul, Turkey*)

Circulating Human Fractalkine is Decreased Post-operatively After Orthopedic and Coronary Bypass Surgery. T. EKERFELDT, J. HELMERSSON-KARLQVIST, T. GORDH, A. LARSSON (*Uppsala, Sweden*)

Circulating miR-18a; A Sensitive Cancer Screening Biomarker in Human Cancer. S. KOMATSU, D. ICHIKAWA, H. TAKESHITA, R. MORIMURA, S. HIRAJIMA, M. TSUJIURA, T. KAWAGUCHI, M. MIYAMAE, H. NAGATA, H. KONISHI, A. SHIOZAKI, E. OTSUJI (*Kyoto, Japan*)

Antioxidant Effects of Lipophilic Tea Polyphenols on Diethylnitrosamine/Phenobarbital-induced Hepatocarcinogenesis in Rats. F. ZHOU, T. SHEN, T. DUAN, Y.-Y. XU, S.C. KHOR, Y.-F. ZHENG, S. HSU, J. DE STEFANO, J. YANG, L.-H. XU, X.-Q. ZHU (*Hangzhou, Zhejiang; Shanghai, PR China; Augusta, GA, USA*)

Anti-inflammatory Effects of Polihexanide and Polyethylene glycol in an In-vitro Study in Chronic Rhinosinusitis. R. BIRK, J. GROSSBAIER, C. ADERHOLD, J. STERN-STRÄTER, K. HÖRMANN, A. SAUTER, J.U. SOMMER (*Heidelberg, Germany*)

Anti-UV Activity of Kampo Medicines and Constituent Plant Extracts: Re-evaluation with Skin Keratinocyte System. T. KATO, S. HINO, N. HORIE, T. SHIMOYAMA, T. KANEKO, K. KUSAMA, H. SAKAGAMI (*Saitama; Tokyo, Japan*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

# CANCER GENOMICS & PROTEOMICS

www.cgp.iarjournals.org

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)  
From VOL. 10 (2013) online – only and open access



## International Online Open Access Journal

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**: For more information please visit our website [www.cgp.iarjournals.org](http://www.cgp.iarjournals.org).

### Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. E-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org); IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iiarjournals.org](http://www.iiarjournals.org)

### A Selection of Recent Papers

Genome-wide Transcriptional Sequencing Identifies Novel Mutations in Metabolic Genes in Human Hepatocellular Carcinoma (HCC). D.M. MEERZAMAN, C. YAN, Q.-R. CHEN, M.N. EDMONSON, C.F. SCHAEFER, R.J. CLIFFORD, B.K. DUNN, L. DONG, R.P. FINNEY, C.M. CULTRARO, Y. HU, Z. YANG, C.V. NGUYEN, J.M. KELLEY, S. CAI, H. ZHANG, J. ZHANG, R. WILSON, L. MESSMER, Y.-H. CHUNG, J.A. KIM, N.H. PARK, M.-S. LYU, I.H. SONG, G. KOMATSOULIS, K.H. BUETOW (*Rockville; Bethesda, MD; Memphis, TN, USA; Seoul; Ulsan; Cheon-An, South Korea*)

Crucial and Novel Cancer Drivers in a Mouse Model of Triple-Negative Breast Cancer. J.P.S. JOHNSON, P. KUMAR, M. KOULNIS, M. PATEL, K. SIMIN (*Worcester, MA; Bethesda, MD; Scranton, PA; New York, NY, USA; Singapore, Singapore*)

Cilia Gene Expression Patterns in Cancer. M. SHPAK, M.M. GOLDBERG, M.C. COWPERTHWAITTE (*Austin TX, USA*)

MicroRNA-150 Is Up-regulated in Extranodal Marginal Zone Lymphoma of MALT Type. N. GEBAUER, J. KUBA, A. SENFT, A. SCHILLERT, V. BERNARD, C. THORNS (*Lübeck, Germany*)

Proteomic Analysis of Soft Tissue Tumor Implants Treated with a Novel Polybisphosphonate. A. ALAIYA, J. FOX, S. BOBIS, G. MATIC, Z. SHINWARI, E. BARHOUSH, M. MÁRQUEZ, S. NILSSON, A.R. HOLMBERG (*Riyadh, Saudi Arabia; Manchester, UK; Stockholm, Sweden*)

Fucoidan-dependent Increased Membrane Component in HepG2: Effect of Fucoidan Is Not Due to Gene Expression. K. HAYAKAWA, T. NAGAMINE (*Tokyo; Gunma, Japan*)

Review: Prospects of Bacterial and Plant Protein-based Immunotoxins for Treatment of Cancer. U.H. WEIDLE, G. TIEFENTHALER, C. SCHILLER, E.H. WEISS, G. GEORGES, U. BRINKMANN (*Penzberg; Munich, Germany*)

A Novel Transmembrane Glycoprotein Cancer Biomarker Present in the X Chromosome. A.P. DELGADO, S. HAMID, P. BRANDAO, R. NARAYANAN (*Boca Raton, FL, USA*)

Rho Kinase Proteins Regulate Global miRNA Expression in Endothelial Cells. J.M. STILES, V. KURISSETTY, D.C. MITCHELL, B.A. BRYAN (*El Paso, TX, USA*)

Gene Expression Profiling of Circulating Natural Killer Cells in Head and Neck Squamous Cell Carcinoma. A. BOTTCHEER, J. OSTWALD, D. KOCZAN, R. KNECHT, B. KRAMP, S. DOMMERICH (*Hamburg; Rostock; Berlin, Germany*)

Serum and Tissue Metabolomics of Head and Neck Cancer. K. YONEZAWA, S. NISHIUMI, J. KITAMOTOMATSUDA, T. FUJITA, K. MORIMOTO, D. YAMASHITA, M. SAITO, N. OTSUKI, Y. IRINO, M. SHINOHARA, M. YOSHIDA, K.-I. NIBU (*Kobe, Japan*)

Isolation of Stem Cells Using Spheroids from Fresh Surgical Specimen: An Analytic Mini-review. I. AVITAL, A. STOJADINOVIC, H. WANG, C. MANNION, W.C.S. CHO, J. WANG, Y.G. MAN (*Richmond, VA; Hackensack, NJ; Washington, DC, USA; Hangzhou, China; Hong Kong, Hong Kong*)

Mutational Analysis of Gastrointestinal Stromal Tumors (GISTs): Procedural Approach for Diagnostic Purposes. R. PALMIROTTA, M.L. DE MARCHIS, G. LUDOVICI, B. LEONE, R. COVELLO, S. CONTI, L. COSTARELLI, D. DELLA-MORTE, P. FERRONI, M. ROSELLI, F. GUADAGNI (*Rome, Italy; Miami, FL, USA*)

Predictive and Prognostic Significance of Sodium Levels in Patients with NSCLC Treated by Erlotinib. M. SVATON, O. FIALA, M. PESEK, F. BRUHA, P. MUKENSNABL, J. RACEK, M. MINARIK, Z. BORTLICEK ( <i>Prague; Brno, Czech Republic</i> ) .....	7461
Clinicopathological Factors Affecting Progression-Free Survival of Patients With Previously Treated Advanced Non-Small Cell Lung Cancer After S-1 Therapy With or Without Bevacizumab. K. MASAGO, S. FUJITA, A. HATA, R. KAJI, K. OHTSUKA, C. OKUDA, J. TAKESHITA, N. KATAKAMI ( <i>Kobe; Nagoya, Japan</i> ) .....	7467
L-[3-18F]- $\alpha$ -Methyltyrosine Uptake by Lymph Node Metastasis Is a Predictor of Complete Response to CRT in Esophageal Cancer. M. SOHDA, T. MIYAZAKI, H. HONJYO, K. HARA, D. OZAWA, S. SUZUKI, N. TANAKA, A. SANO, M. SAKAI, T. YOKOBORI, M. NAKAJIMA, M. FUKUCHI, H. KATO, T. HIGUCHI, Y. TSUSHIMA, H. KUWANO ( <i>Maebashi; Mibu, Japan</i> ) .....	7473
Appendix to Anticancer Research Vol. 34, No 10, October 2014. Abstracts of the 9th International Conference of Anticancer Research, October 6-10, 2014, Sithonia, Greece .....	7479
Errata .....	7485
Index .....	7487

Assessment of Risk of Late Rectal Bleeding for Patients with Prostate Cancer Started on Anticoagulation Before or After Radiation Treatment. D. SCHREIBER, S.-C. CHEN, J. RINEER, M. WORTH, T. TELIVALA, D. SCHWARTZ ( <i>New York; Brooklyn, NY; Orlando, FL, USA</i> ) .....	7367
Frequency and Predisposing Factors for Interfractional Rectal Displacement Requiring Repeated Precaution in Prostate Cancer Patients Treated with Image-Guided Intensity-Modulated Radiation Therapy. K. IWAMA, H. YAMAZAKI, T. NISHIMURA, Y. OOTA, N. AIBE, S. NAKAMURA, H. IKENO, K. YOSHIDA, H. OKABE ( <i>Kyoto; Osaka, Japan</i> ) .....	7373
Palifermin in Children Undergoing Autologous Stem Cell Transplantation: a Matched-pair Analysis. K. CZYZEWSKI, R. DEBSKI, A. KRENSKA, M. WYSOCKI, J. STYCZYNSKI ( <i>Bydgoszcz, Poland</i> ) .....	7379
Analysis of Intrafractional Organ Motion by Megavoltage Computed Tomography in Patients with Lung Cancer Treated with Image-guided Stereotactic Body Radiotherapy Using Helical Tomotherapy. N. AIBE, H. YAMAZAKI, T. NISHIMURA, Y. OOTA, K. IWAMA, S. NAKAMURA, H. IKENO, K. YOSHIDA, H. OKABE, K. YAMADA ( <i>Kyoto; Osaka, Japan</i> ) .....	7383
Risk Factors for Pericardial Effusion in Patients with Stage I Esophageal Cancer Treated with Chemoradiotherapy. K. TAMARI, F. ISOHASHI, Y. AKINO, O. SUZUKI, Y. SEO, Y. YOSHIOKA, Y. HAYASHI, T. NISHIDA, T. TAKEHARA, M. MORI, Y. DOKI, K. OGAWA ( <i>Osaka, Japan</i> ) .....	7389
<i>Ponticulus posticus</i> is a Frequent Radiographic Finding on Lateral Cephalograms in Nevroid Basal Cell Carcinoma Syndrome (Gorlin–Goltz Syndrome). R.E. FRIEDRICH ( <i>Hamburg, Germany</i> ) .....	7395
Does Pulmonary Resection Promote the Progression of Unresected Ground-glass Nodules? K. UEDA, F. SANO, J. MURAKAMI, M. HAYASHI, T. KOBAYASHI, Y. KUNIHIRO, K. HAMANO ( <i>Yamaguchi, Japan</i> ) .....	7401
Post-operative Aspirin Use and Colorectal Cancer-specific Survival in Patients with Stage I-III Colorectal Cancer. C.H. GOH, W.Q. LEONG, M.H. CHEW, Y.S. PAN, L.K.H. TONY, L. CHEW, I.B.H. TAN, H.C. TOH, C.L. TANG, W.P.C. FU, W.K. CHIA ( <i>Singapore, Singapore</i> ) .....	7407
Detection of Circulating Tumor Cells in Bladder Cancer Using Multiplex PCR Assays. I. LEOTSAKOS, P. DIMOPOULOS, E. GKIOKA, P. MSAOUEL, A. NEZOS, K.G. STRAVODIMOS, M. KOUTSILIERIS, C.A. CONSTANTINIDES ( <i>Athens, Greece; Bronx, NY, USA</i> ) .....	7415
Mesothelin in Serum and Pleural Effusion in the Diagnosis of Malignant Pleural Mesothelioma with Non-positive Cytology. M.C. FRANCESCHINI, P. FERRO, P.A. CANESSA, E. BATTOLLA, P. DESSANTI, A. VALENTINO, L. CASOLARI, V. FONTANA, R. PEZZI, F. FEDELI, M.P. PISTILLO, S. RONCELLA ( <i>La Spezia; Genova, Italy</i> ) .....	7425
Analysis of Preoperative Serum Levels of MMP1, -2, and -9 in Patients with Site-specific Head and Neck Squamous Cell Cancer. D. KALFERT, M. LUDVIKOVA, O. TOPOLCAN, J. WINDRICOVA, E. MALIROVA, M. PESTA, P. CELAKOVSKY ( <i>Prague; Pilsen; Hradec Kralove, Czech Republic</i> ) .....	7431
Kinetics of Circulating Levels of miR-195, miR-155 and miR-21 in Patients with Breast Cancer Undergoing Mastectomy. M. IGGLEZOU, K. VARELI, G.K. GEORGIU, I. SAINIS, E. BRIASOULIS ( <i>Ioannina, Greece</i> ) .....	7443
Baseline Central Nervous System Magnetic Resonance Imaging in Early Detection of Trilateral Retinoblastoma: Pitfalls in the Diagnosis of Pineal Gland Lesions. M.A. DE IORIS, P. VALENTE, F. RANDISI, L. BUZZONETTI, A. CARAI, R. COZZA, F. DEL BUFALO, A. ROMANZO, A. ANGIONI, A. CACCHIONE, B. BERNARD, A. MASTRONUZZI ( <i>Rome, Italy</i> ) .....	7449
Esophageal Carcinosarcoma: Management and Prognosis at a Single Italian Series. F. CAVALLIN, M. SCARPA, R. ALFIERI, M. CAGOL, A. RUOL, M. RUGGE, E. ANCONA, C. CASTORO ( <i>Padua, Italy</i> ) .....	7455

Portal Vein Embolisation with Application of Haematopoietic Stem Cells in Patients with Primarily or Non-resectable Colorectal Liver Metastases. V. TRESKA, V. LISKA, J. FICHTL, D. LYSAK, H. MIRKA, J. BRUHA, P. DURAS, I. TRESKOVA, J. NAHLIK, V. SIMANEK, O. TOPOLCAN ( <i>Pilsen, Czech Republic</i> ) .....	7279
Febuxostat for Management of Tumor Lysis Syndrome Including its Effects on Levels of Purine Metabolites in Patients with Hematological Malignancies - A Single Institution's, Pharmacokinetic and Pilot Prospective Study. M. TAKAI, T. YAMAUCHI, M. OOKURA, Y. MATSUDA, K. TAI, S. KISHI, A. YOSHIDA, H. IWASAKI, T. NAKAMURA, T. UEDA ( <i>Fukui, Japan</i> ) .....	7287
Feasibility Study of Supportive Care Using Lafutidine, a Histamine H2 Receptor Antagonist, to Prevent Gastrointestinal Toxicity During Chemotherapy for Gastric Cancer. T. NAMIKAWA, E. MUNEKAGE, H. MAEDA, H. KITAGAWA, M. KOBAYASHI, K. HANAZAKI ( <i>Kochi, Japan</i> ) .....	7297
Ovarian Sarcoma Carries a Poorer Prognosis than Ovarian Epithelial Cancer Throughout all FIGO Stages: A Single-center Case-control Matched Study. N. BACALBASA, I. BALESU, S. DIMA, I. POPESCU ( <i>Bucharest, Romania</i> ) .....	7303
Comparison of Two Dose Levels of Stereotactic Radiosurgery for 1-3 Brain Metastases from Non-small Cell Lung Cancer. D. RADES, S. HUTTENLOCHER, M. DAHLKE, D. HORNING, O. BLANCK, P.V. THAI, N.T. TRANG, M.T. KHOA, S.E. SCHILD ( <i>Lübeck; Hamburg; Güstrow, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA</i> ) .....	7309
Fatal Bilateral Pneumonitis After Locoregional Thoracic Chemoradiation in a Transplanted Patient Under Immunosuppressive Therapy. P.G. WESTHOFF, D.K.M. DE RUYSSCHER, F.M.N.H. SCHRAMMEL, M. BULBUL, A. DENDOOVEN, S.Y. EL SHAROUNI ( <i>Utrecht; Nieuwegein, The Netherlands; Leuven, Belgium</i> ).....	7315
Safety and Efficacy of Pegylated Liposomal Doxorubicinbased Adjuvant Chemotherapy in Patients with Stage I-III Triple-negative Breast Cancer. M.-Y. LIEN, L.-C. LIU, H.-C. WANG, M.-H. YEH, C.-J. CHEN, S.-P. YEH, L.-Y. BAI, Y.-M. LIAO, C.-Y. LIN, C.-Y. HSIEH, C.-C. LIN, L.-Y. LI, P.-H. LIN, C.-F. CHIU ( <i>Taichung; Taipei, Taiwan, ROC</i> ).....	7319
Melatonin in Patients with Cancer Receiving Chemotherapy: A Randomized, Double-blind, Placebo-controlled Trial. A. SOOKPRASERT, N.P. JOHNS, A. PHUNMANEE, P. PONGTHAI, A. CHEAWCHANWATTANA, J. JOHNS, J. KONSIL, P. PLAIMEE, S. PORASUPHATANA, S. JITPIMOLMARD ( <i>Khon Kaen, Thailand</i> ).....	7327
Radiation Recall Gastritis Secondary to Erlotinib in a Patient with Pancreatic Cancer. C. GRAZIANI, S. HEGDE, M.W. SAIF ( <i>Boston, MA, USA</i> ) .....	7339
Two-team Simultaneous Total Radical Vulvectomy and Inguino-femoral Lymphadenectomy via Separate Incisions for Locally Advanced (FIGO Stages IB $\geq$ 4 cm-III) Squamous Vulvar Cancer. M. FAMBRINI, F. SORBI, G. SISTI, V. CHECCUCCI, G. CARITI, V. SCOTTI, E. TINACCI, I. TURRINI, M. MICAGLIO, A. DE MAGNIS ( <i>Florence, Italy</i> ).....	7345
Expression of Adhesion Molecules and the Proliferative Activity of Carcinosarcoma of the Ovary. H. HIRANO, T. KIZAKI, T. ITO, A. OKIMURA, K. YAMANEGI, K. NAKASHO ( <i>Hyogo, Japan</i> ) .....	7351
A Case Series of Patients with HER2-Overexpressed Primary Metastatic Gastroesophageal Adenocarcinoma. P. CINAR, S.M. CALKINS, A.P. VENUK, R.K. KELLEY ( <i>San Francisco, CA, USA</i> ) .....	7357
Sunitinib-induced Complete Response in Metastatic Renal Cancer Expressing Neuroendocrine Markers: A New Predictive Factor? D. GAMBINI, E. LOCATELLI, U. GIANELLI, C. BAREGGI, B. GALASSI, R. VISINTIN, S. MASSIRONI, P.G. DELL'ORTO, M. TOMIROTTI ( <i>Milan, Italy</i> ) .....	7361

*Clinical Studies*

<i>In Vitro</i> Chemoresponse in Metachronous Pairs of Ovarian Cancers. H.J. DALTON, J.V. FIORICA, R.P. EDWARDS, I. BENJAMIN, R.P. ROCCONI, F.O. RECIO, J.L. LOVECCHIO, M.O. BURRELL, M.S. SHAHIN, E.C. GRENDYS, D. WANG, T. WANG, B.J. MONK (Houston, TX; Sarasota; Boca Raton; Fort Myers, FL; Pittsburgh; Abington, PA; Phoenix, AZ; Mobile, AL; Manhasset, NY; Atlanta, GA, USA) .....	7191
Independence of Cytotoxic Drug Sensitivity Profiles and Receptor Subtype of Invasive Ductal Breast Carcinoma Demonstrated by the Histoculture Drug Response Assay (HDRA). K.Y. KIM, B.W. CHUNG, I. YANG, M.B. KIM, R.M. HOFFMAN (Seoul, Republic of Korea; San Diego, CA, USA) .....	7197
Estrogen and Androgen Receptors in Inflammatory Fibroid Polyp (Vanek's Tumor): Case Report. Z. JUKIC, Z. FERENCIC, P. RADULOVIC, A. MIJIC, A. FUCIC (Nova Gradiska; Zagreb, Croatia) .....	7203
MicroRNA Expression in Early Mycosis Fungoides Is Distinctly Different from Atopic Dermatitis and Advanced Cutaneous T-Cell Lymphoma. U. RALFKIAER, L. LINDAL, T. LITMAN, L.-M. GJERDRUM, C.B. AHLER, R. GNIADECKI, T. MARSTRAND, S. FREDHOLM, L. IVERSEN, M.A. WASIK, C.M. BONEFELD, C. GEISLER, T. KREJSGAARD, C. GLUE, M.A. RØPKE, A. WOETMANN, L. SKOV, K. GRØNBÆK, N. ODUM (Copenhagen; Aarhus; Ballerup; Vedbaek, Denmark; Philadelphia, PA, USA) .....	7207
Clinical Significance of an Inflammation-based Prognostic System for Gastric Cancer Patients with a Preoperative Normal Serum Level of Carcinoembryonic Antigen. M. ISHIZUKA, Y. OYAMA, A. ABE, K. TAGO, G. TANAKA, K. KUBOTA (Tochigi, Japan) .....	7219
Outcome of Esophagojejunostomy During Totally Laparoscopic Total Gastrectomy: A Single-Center Retrospective Study. Y. HIYOSHI, E. OKI, K. ANDO, S. ITO, H. SAEKI, M. MORITA, H. BABA, Y. MAEHARA (Fukuoka; Kumamoto, Japan) .....	7227
Simultaneous 24 h-Infusion of High-dose 5-Fluorouracil and Sodium-Folate as Alternative to Capecitabine in Advanced Breast Cancer. A. TERJUNG, S. KUMMER, M. FRIEDRICH (Krefeld, Germany) .....	7233
Concomitant Capecitabine with Hepatic Delivery of Drug Eluting Beads in Metastatic Colorectal Cancer. O. AKINWANDE, A. MILLER, D. HAYES, R. O'HARA, D. TOMALTY, R.C.G. MARTIN (Pittsburgh, PA; Louisville, KY; Little Rock, AR; Colorado Springs, CO; Huntsville, AL, USA) .....	7239
Comparison of Two Transarterial Chemoembolization Strategies for Hepatocellular Carcinoma. J. TAVERNIER, P. FAGNONI, P. CHABROT, B. GUIU, L. VADOT, S. AHO, L. BOYER, A. ABERGEL, P. HILLON, V. SAUTOU, M. BOULIN (Clermont-Ferrand; Dijon, France) .....	7247
Association Between Radiation Dose and Pathological Complete Response After Preoperative Radiochemotherapy in Esophageal Squamous Cell Cancer. A.D. ORDU, C. NIEDER, H. GEINITZ, V. SCHERER, P.G. KUP, T. SCHUSTER, S.E. COMBS, K. FAKHRIAN (München; Bochum, Germany; Bodø; Tromsø, Norway; Linz, Austria; Montreal, Canada) .....	7255
Preoperative Serum C-Reactive Protein and its Prognostic Significance in Patients with Stage III-IV Colorectal Cancer. F. LUMACHI, S.M.M. BASSO, D.A. SANTEUFEMIA, M. ERMANI, G. LO RE, G.B. CHIARA (Padova; Pordenone; Alghero, Italy) .....	7263
Congestive Heart Failure Secondary to Gemcitabine Nab-paclitaxel in Patients with Pancreatic Cancer. P. JOHN, H. BUTLER, M.W. SAIF (Boston, MA, USA) .....	7267
Polaprezinc Prevents Oral Mucositis in Patients Treated with High-dose Chemotherapy Followed by Hematopoietic Stem Cell Transplantation. H. HAYASHI, R. KOBAYASHI, A. SUZUKI, M. ISHIHARA, N. NAKAMURA, J. KITAGAWA, N. KANEMURA, S. KASAHARA, K. KITAICHI, T. HARA, H. TSURUMI, H. MORIWAKI, Y. ITOH (Gifu, Japan) .....	7271



Growth-modulatory Effects of Heparin and VEGF165 on the Choriocarcinoma Cell-line JEG-3 and its Expression of Heparanase. M.K. BOHLMANN, J.-C. HOERSTER, D. BUNDSCHUH, P. BOEMICKE, D.W. LUEDDERS, F. KÖSTER ( <i>Lübeck; Oldenburg, Germany</i> ) .....	7071
Synthesis of a Monofunctional Platinum Compound and its Activity Alone and in Combination with Phytochemicals in Ovarian Tumor Models. L. ARZUMAN, P. BEALE, J.Q. YU, N. PROSCHOGO, F. HUQ ( <i>Lidcombe; Concord; Sydney, NSW, Australia</i> ) .....	7077
Cleaved CD147 Shed from the Surface of Malignant Melanoma Cells Activates MMP2 Produced by Fibroblasts. M. HATANAKA, Y. HIGASHI, T. FUKUSHIGE, N. BABA, K. KAWAI, T. HASHIGUCHI, J. SU, W. ZENG, X. CHEN, T. KANEKURA ( <i>Kagoshima, Japan; Changsha, PR China</i> ) .....	7091
Tanshinone IIA Inhibits Gastric Carcinoma AGS Cells Through Increasing p-p38, p-JNK and p53 but Reducing p-ERK, CDC2 and Cyclin B1 Expression. C.-C. SU ( <i>Changhua; Taichung, Taiwan, ROC</i> ) .....	7097
Cisplatin at Sub-toxic Levels Mediates Integrin Switch in Lung Cancer Cells. A. MAIUTHED, P. CHANVORACHOTE ( <i>Bangkok, Thailand</i> ) .....	7111
Numerical and Structural Chromosomal Anomalies in Undifferentiated Pleomorphic Sarcoma. M. BECERIKLI, S. WIECZOREK, I. STRICKER, S. NAMBIAR, A. RITTIG, J.T. EPPLER, A. TANNAPFEL, M. LEHNHARDT, L. STEINSTRÄESSER, F. JACOBSEN ( <i>Bochum, Germany</i> ) .....	7119
A Positive Correlation Between Neutrophils in Regional Lymph Nodes and Progression of Gastric Cancer. M. TOKUMOTO, H. TANAKA, M. OHIRA, Y. GO, Y. OKITA, K. SAKURAI, T. TOYOKAWA, N. KUBO, K. MUGURUMA, K. MAEDA, T. SAWADA, K. HIRAKAWA ( <i>Osaka, Japan</i> ) .....	7129
The Potential of <i>SIRT6</i> and <i>SIRT7</i> as Circulating Markers for Head and Neck Squamous Cell Carcinoma. C.-T. LU, C.-M. HSU, P.-M. LIN, C.-C. LAI, H.-C. LIN, C.-H. YANG, H.-H. HSIAO, Y.-C. LIU, H.Y.-H. LIN, S.-F. LIN, M.-Y. YANG ( <i>Kaohsiung City; Tao-Yuan, Taiwan, ROC</i> ) .....	7137
Induction of Apoptosis by Eicosapentaenoic Acid in Esophageal Squamous Cell Carcinoma. K. MIZOGUCHI, H. ISHIGURO, M. KIMURA, H. TAKAHASHI, N. SAKAMOTO, T. TANAKA, H. TAKEYAMA ( <i>Nagoya, Japan</i> ) .....	7145
Cell-cycle Disturbance and Induction of Programmed Death by New Formamidine Analogs of Daunorubicin. M. STOJAK, M. ŁUKAWSKA, I. OSZCZAPOWICZ, M. OPYDO-CHANEK, L. MAZUR ( <i>Kraków; Warsaw, Poland</i> ) .....	7151
Comparison of Prostate Cancer Gene 3 Score, Prostate Health Index and Percentage Free Prostate-specific Antigen for Differentiating Histological Inflammation from Prostate Cancer and Other Non-neoplastic Alterations of the Prostate at Initial Biopsy. S. DE LUCA, R. PASSERA, E. BOLLITO, M. MANFREDI, R.M. SCARPA, A. SOTTILE, D.F. RANDONE, F. PORPIGLIA ( <i>Torino; Candiolo, Italy</i> ) .....	7159
<i>PSCA</i> and <i>MUC1</i> Gene Polymorphisms Are Linked with Gastric Cancer and Pre-malignant Gastric Conditions. J. KUPCINSKAS, T. WEX, A. LINK, R. BARTUSEVICIUTE, M. DEDELAITE, G. KEVALAITE, M. LEJA, J. SKIECEVICIENE, G. KIUDELIS, L. JONAITIS, L. KUPCINSKAS, P. MALFERTHEINER ( <i>Kaunas, Lithuania; Magdeburg, Germany; Riga, Latvia</i> ) .....	7167
An Improved and Versatile Immunosuppression Protocol for the Development of Tumor Xenograft in Mice. M. JIVRAJANI, M.V. SHAIKH, N. SHRIVASTAVA, M. NIVSARKAR ( <i>Ahmedabad, India</i> ) .....	7177
Regulatory T-Cells and Micrometastasis in Lymph Nodes of Stage I NSCLC. T. HANAGIRI, M. FUKUMOTO, Y. KOYANAGI, Y. FURUTANI, F. TANAKA ( <i>Fukuoka; Kitakyushu, Japan</i> ) .....	7185

Evaluation of a Special Combination of Glucan with Organic Selenium Derivative in Different Murine Tumor Models. V. VETVICKA, M. F. PINATTO-BOTELHO, A.A. DOS SANTOS, C.A.F. DE OLIVEIRA (Louisville, KY, USA.; São Paulo; Lençóis Paulista, SP, Brazil) .....	6939
Differential Spheroid Formation by Oral Cancer Cells. CARLIN LEE, CASEY LEE, A. ATAKILIT, A. SIU, D.M. RAMOS (San Francisco, CA; San Antonio, TX, USA) .....	6945
A Novel Cytidine Analog, RX-3117, Shows Potent Efficacy in Xenograft Models, even in Tumors that Are Resistant to Gemcitabine. M.Y. YANG, Y.B. LEE, C.-H. AHN, J. KAYE, T. FINE, R. KASHI, O. OHNE, K. SMID, G.J. PETERS, D.J. KIM (Rockville, MD, USA; Petach Tikva, Israel; Amsterdam, The Netherlands) .....	6951
Expression of MSH2 and MSH6 on a Tissue Microarray in Patients with Osteosarcoma. T. JENTZSCH, B. ROBL, M. HUSMANN, B. BODE-LESNIEWSKA, B. FUCHS (Zürich, Switzerland) .....	6961
p53 Up-regulation During Colorectal Carcinogenesis. C.A. RUBIO, M. RODESJÖ, A. DUVANDER, M. MATHIES, L. GARBERG, J. SHETYE (Stockholm, Sweden) .....	6973
Inhibition of P-TEFb by DRB Suppresses SIRT1/CK2 $\alpha$ Pathway and Enhances Radiosensitivity of Human Cancer Cells. Z.-Q. WANG, C.L. JOHNSON, A. KUMAR, D.P. MOLKENTINE, J.M. MOLKENTINE, T. RABIN, K.A. MASON, L. MILAS, U. RAJU (Houston, TX, USA) .....	6981
Combination of Arginine Deprivation with TRAIL Treatment as a Targeted-Therapy for Mesothelioma. M. WANGPAICHITR, C. WU, G. BIGFORD, G. THEODOROPOULOS, M. YOU, Y.Y. LI, J. VERONA-SANTOS, L.G. FEUN, D.M. NGUYEN, N. SAVARAJ (Miami, FL, USA) .....	6991
Genotype of DNA Double-strand Break Repair Gene <i>XRCC7</i> Is Associated with Lung Cancer Risk in Taiwan Males and Smokers. T.-C. HSIA, W.-S. CHANG, W.-C. CHEN, S.-J. LIANG, C.-Y. TU, H.-J. CHEN, J.-A. LIANG, C.-W. TSAI, C.-M. HSU, C.-H. TSAI, D.-T. BAU (Taichung, Taiwan, ROC) .....	7001
Doxorubicin Overcomes Resistance to Drozitumab by Antagonizing Inhibitor of Apoptosis Proteins (IAPs). I. ZINONOS, A. LABRINIDIS, V. LIAPIS, S. HAY, V. PANAGOPOULOS, M. DENICHILO, V. PONOMAREV, W. INGMAN, G.J. ATKINS, D.M. FINDLAY, A.C.W. ZANNETTINO, A. EVDOKIOU (Adelaide, SA, Australia; New York, NY, USA) .....	7007
MAD2 Expression in Oral Squamous Cell Carcinoma and its Relationship to Tumor Grade and Proliferation. C. RIZZARDI, L. TORELLI, M. SCHNEIDER, F. GIUDICI, L. ZANDONA, M. BIASOTTO, R. DI LENARDA, M. MELATO (Trieste; Gorizia, Italy) .....	7021
The <i>N</i> -Nitrosodiethylamine Mouse Model: Sketching a Timeline of Evolution of Chemically-induced Hepatic Lesions. R.M.G DA COSTA, N. PAULA-SANTOS, A. FAUSTINO ROCHA, A. COLAÇO, C. LOPES, P.A. OLIVEIRA (Porto; Vila Real; Vairão, Portugal) .....	7029
Interleukin-10 ( <i>IL-10</i> ) Promoter Genotypes Are Associated with Lung Cancer Risk in Taiwan Males and Smokers. T.-C. HSIA, W.-S. CHANG, S.-J. LIANG, W.-C. CHEN, C.-Y. TU, H.-J. CHEN, M.-D. YANG, C.-W. TSAI, C.-M. HSU, C.-H. TSAI, D.-T. BAU (Taichung, Taiwan, ROC) .....	7039
Lectin Histochemistry of Murine WAP-T Mammary Cancer Reveals Similar Glycoconjugate Changes to Those in Human Breast Cancer. S. SCHREIBER, A. GOCHT, F. WEGWITZ, W. DEPPERT, U. SCHUMACHER (Hamburg; Lübeck, Germany) .....	7045
<i>In Vitro</i> Oxygen Availability Modulates the Effect of Artesunate on HeLa cells. J. MURRAY, S. GANNON, S. RAWE, J.E.J. MURPHY (Sligo; Dublin, Ireland) .....	7055
Incomplete Epithelial–Mesenchymal Transition in p16-positive Squamous Cell Carcinoma Cells Correlates with $\beta$ -Catenin Expression. C. UMBREIT, J. FLANJAK, C. WEISS, P. ERBEN, C. ADERHOLD, A. FABER, J. STERN-STRAETER, K. HOERMANN, J.D. SCHULTZ (Mannheim, Germany) .....	7061